MVT-602

MVT-602
Clinical data
Other names	RVT-602; TAK-448
Identifiers
	IUPAC name (2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide; or; Ac-D-Tyr-Hyp-Asn-Thr-Phe-Unk-Leu-Arg(Me)-Trp-NH2;
CAS Number	1234319-68-6;
PubChem CID	46700761;
IUPHAR/BPS	10222;
DrugBank	DB11975;
UNII	YO029HR229;
ChEMBL	ChEMBL3924151;
CompTox Dashboard (EPA)	DTXSID401337050 ;
Chemical and physical data
Formula	C58H80N16O14
Molar mass	1225.376 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=NC)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H](CC5=CC=C(C=C5)O)NC(=O)C)O)O;
	InChI InChI=1S/C58H80N16O14/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+/m1/s1; Key:MWXWMWSUUYXMRA-GRKBUMBKSA-N;

MVT-602 (other developmental code names RVT-602, TAK-448) is a kisspeptin receptor agonist which is under development for the treatment of female infertility and hypogonadism.^[1]^[2] It has been found to increase luteinizing hormone levels in premenopausal women.^[2] As of March 2021, MVT-602 is in phase 2 clinical trials for the treatment of female infertility and hypogonadism.^[1] It was also under development for the treatment of prostate cancer, but development for this indication was discontinued.^[1]

References

^ ^a ^b ^c "MVT 602". Adis Insight. Springer Nature Switzerland AG.
^ ^a ^b Abbara A, Eng PC, Phylactou M, Clarke SA, Richardson R, Sykes CM, et al. (December 2020). "Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders". The Journal of Clinical Investigation. 130 (12): 6739–6753. doi:10.1172/JCI139681. PMC 7685751. PMID 33196464.

External links

MVT-602 - AdisInsight

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] "MVT 602". Adis Insight. Springer Nature Switzerland AG.

[pmid33196464-2] Abbara A, Eng PC, Phylactou M, Clarke SA, Richardson R, Sykes CM, et al. (December 2020). "Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders". The Journal of Clinical Investigation. 130 (12): 6739–6753. doi:10.1172/JCI139681. PMC 7685751. PMID 33196464.

[1]

[2]